Oncology and Hematology

97-112 of 124

• 

  RestartResume

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  RestartResume

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  MinuteCE®

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  RestartResume

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  MinuteCE®

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  RestartResume

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  1.00 program credit

  • 

    

    Ritu Salani, MD, MBA

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  MinuteCE®

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  RestartResume

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  1.00 program credit

  • 

    

    Ritu Salani, MD, MBA

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD, MBA

  1.00 program credit

• 

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  MinuteCE®

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  1.00 program credit

  • 

    

    Ritu Salani, MD, MBA

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  MinuteCE®

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  MinuteCE®

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  MinuteCE®

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer

  1.00 credit 10 episodes

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 credit 10 episodes

• 

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  RestartResume

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  MinuteCE®

  Application of guidelines-recommended broad molecular profiling to patients with NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  MinuteCE®

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  MinuteCE®

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  RestartResume

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  MinuteCE®

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  RestartResume

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  MinuteCE®

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• Previous
• 1
• 2
• …
• 5
• 6
• 7
• 8
• Next